JCR Pharmaceuticals Co., Ltd. announced that the U.S. Food and Drug Administration granted orphan drug designation to JR-441, an investigational drug for the treatment of mucopolysaccharidosis.
Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032
On track to share interim Phase 1b data in H1 2024
.